Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI

Sei Investments Co. acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 52,235 shares of the company’s stock, valued at approximately $1,003,000.

A number of other large investors have also recently made changes to their positions in DNLI. B. Metzler seel. Sohn & Co. AG purchased a new position in Denali Therapeutics during the 4th quarter worth approximately $1,841,000. Pictet Asset Management Holding SA lifted its stake in Denali Therapeutics by 166.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,329,108 shares of the company’s stock valued at $21,981,000 after buying an additional 829,946 shares during the last quarter. UBS Group AG lifted its stake in Denali Therapeutics by 19.5% in the fourth quarter. UBS Group AG now owns 2,404,704 shares of the company’s stock valued at $39,702,000 after buying an additional 392,351 shares during the last quarter. D.A. Davidson & CO. acquired a new stake in shares of Denali Therapeutics in the fourth quarter valued at approximately $1,765,000. Finally, Profund Advisors LLC boosted its holdings in shares of Denali Therapeutics by 78.4% in the fourth quarter. Profund Advisors LLC now owns 71,634 shares of the company’s stock valued at $1,183,000 after acquiring an additional 31,478 shares during the period. 92.92% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DNLI. BTIG Research reaffirmed a “buy” rating and issued a $39.00 target price on shares of Denali Therapeutics in a report on Monday, May 11th. Robert W. Baird set a $34.00 price target on shares of Denali Therapeutics in a research note on Friday, August 7th. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a research report on Monday, June 22nd. Wedbush restated an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th. Finally, Morgan Stanley upped their target price on shares of Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $35.92.

Denali Therapeutics Trading Up 2.3%

NASDAQ DNLI opened at $25.27 on Thursday. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $4.04 billion, a P/E ratio of -8.90 and a beta of 1.01. Denali Therapeutics Inc. has a 52-week low of $12.58 and a 52-week high of $27.30. The firm has a 50-day moving average price of $23.85 and a 200 day moving average price of $21.43.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same quarter in the previous year, the company earned ($0.72) earnings per share. Equities research analysts expect that Denali Therapeutics Inc. will post -2.61 EPS for the current year.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.